TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34318970

Group type: EXPERIMENTAL
Intervention: Burnout
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Work system factors
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Individual mediating factors
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Lower levels of burnout
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Consequences of burnout
Number of subjects: 397
Study: 34265412

Group type: EXPERIMENTAL
Intervention: Frailty (FI ≥ 0.25)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors (CVRF)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Interaction between frailty and CVRF
Number of subjects: 339
Study: 35930018

Group type: EXPERIMENTAL
Intervention: Acarbose (n=44)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vildagliptin (n=48)
Number of subjects: 100
Study: 32090492

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) delivered on perineal area 5 minutes twice daily for 28 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Number of subjects: 27
Study: 33176660

Group type: COMPARATOR
Intervention: Traditional medications (RAAS blockers)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dapagliflozin added to traditional medications
Number of subjects: 60
Study: 36355633

Group type: EXPERIMENTAL
Intervention: Mental health chatbot (XiaoE)
Number of subjects: 148

Group type: COMPARATOR
Intervention: E-book
Number of subjects: 148

Group type: COMPARATOR
Intervention: General chatbot (Xiaoai)
Number of subjects: 148

Group type: COMPARATOR
Intervention: E-book and General chatbot (Xiaoai)
Number of subjects: 148
Study: 35118763

Group type: EXPERIMENTAL
Intervention: PACT (Physiotherapy informed by Acceptance and Commitment Therapy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PACT
Number of subjects: 72
Study: 33536506

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 2123
Study: 32433572

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-chitosan gel
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Number of subjects: 21

Group type: COMPARATOR
Intervention: Neutral water-based gel (placebo)
Number of subjects: 21
Study: 34348352

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.1% cream (BMV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate 1% cream (HC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% cream (MPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream (PIM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active agent-free base cream (Dermatop® Basiscreme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 33509248

Group type: EXPERIMENTAL
Intervention: Knee arthroscopy with infrapatellar fat pad cell concentrates containing mesenchymal stromal cells
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular knee arthroscopic therapy
Number of subjects: 60
Study: 35994013

Group type: EXPERIMENTAL
Intervention: Norepinephrine 0.05–0.2 µg/kg/min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Norepinephrine and Placebo
Number of subjects: 80
Study: 33622026

Group type: EXPERIMENTAL
Intervention: Pro-active, absolute cardiovascular risk-guided approach
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 189
Study: 32715744

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham ultrasound treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Both groups (Pulsed ultrasound and Sham ultrasound)
Number of subjects: 96
Study: 35968570

Group type: EXPERIMENTAL
Intervention: IM20 × 3
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: IM20 × 4
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: IM60 × 4
Number of subjects: 215
Study: 34323922

Group type: EXPERIMENTAL
Intervention: Chemoradiation and metformin
Number of subjects: 167

Group type: COMPARATOR
Intervention: Chemoradiation alone (Control)
Number of subjects: 167
Study: 35650577

Group type: EXPERIMENTAL
Intervention: Standard Operating Procedure (SOP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Second Workshop (SW)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 71
Study: 32522171

Group type: EXPERIMENTAL
Intervention: PCNL
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: MiniPerc (MP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Ultraminiperc (UMP)
Number of subjects: 132
Study: 35575085

Group type: EXPERIMENTAL
Intervention: Enhanced e‐cigarette coaching (EEC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Quitline treatment as usual (TAU)
Number of subjects: 96
Study: 34561340

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study: 33271092

Group type: EXPERIMENTAL
Intervention: 3 months of adjuvant chemotherapy (CAPOX or FOLFOX)
Number of subjects: 12835

Group type: COMPARATOR
Intervention: 6 months of adjuvant chemotherapy (CAPOX or FOLFOX)
Number of subjects: 12835

Group type: EXPERIMENTAL
Intervention: CAPOX (3 months)
Number of subjects: 12835

Group type: COMPARATOR
Intervention: CAPOX (6 months)
Number of subjects: 12835

Group type: EXPERIMENTAL
Intervention: FOLFOX (3 months)
Number of subjects: 12835

Group type: COMPARATOR
Intervention: FOLFOX (6 months)
Number of subjects: 12835

Group type: EXPERIMENTAL
Intervention: Overall survival (3 months vs 6 months)
Number of subjects: 12835

Group type: EXPERIMENTAL
Intervention: Overall survival (CAPOX)
Number of subjects: 12835

Group type: EXPERIMENTAL
Intervention: Overall survival (FOLFOX)
Number of subjects: 12835

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 12835
Study: 35283258

Group type: EXPERIMENTAL
Intervention: Personalized music intervention (Music Care© application)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Audiobook control condition
Number of subjects: 24
Study: 34039331

Group type: EXPERIMENTAL
Intervention: Targeted eccentric calf muscle exercises three times per week alongside regular training.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Regular training only (Control group).
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Comparison of both groups.
Number of subjects: 47
Study: 33568389

Group type: EXPERIMENTAL
Intervention: Belimumab intravenous treatment (HDA1)
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Belimumab intravenous treatment (HDA2)
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Belimumab subcutaneous treatment (HDA1)
Number of subjects: 1629

Group type: EXPERIMENTAL
Intervention: Belimumab subcutaneous treatment (HDA2)
Number of subjects: 1629

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 1629
Study: 32376477

Group type: EXPERIMENTAL
Intervention: Preoperative resistance training (RT), twice a week for 10 weeks prior to THA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Care-as-usual (CG)
Number of subjects: 80
Study: 36294155

Group type: EXPERIMENTAL
Intervention: Krill oil (3 g/daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mineral oil (3 g/daily)
Number of subjects: 26
Study: 34674300

Group type: EXPERIMENTAL
Intervention: Early functional mobilization (EFM), immediate weightbearing and ankle motion for 6 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard treatment (ST), 2 weeks of unloading in a plaster cast followed by 4 weeks of weightbearing in an orthosis
Number of subjects: 47
Study: 32570775

Group type: EXPERIMENTAL
Intervention: Flavonoid-rich orange juice (FR), 380 mL daily, 600 ± 5.4 mg flavonoids
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flavonoid-low orange cordial (FL), 380 mL daily, 108 ± 2.6 mg flavonoids
Number of subjects: 40
Study: 36386033

Group type: EXPERIMENTAL
Intervention: PIA intervention (PC‐supported case management with PIA‐ICT and eLearning)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: PIA intervention
Number of subjects: 848

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 848
Study: 33157378

Group type: EXPERIMENTAL
Intervention: Exposed to bushfires
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control (not exposed to bushfires)
Number of subjects: 589
Study: 33303444

Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) aimed to maintain DO2i at ≥360 mL/min/m2
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group with perfusion strategy based on body surface area and temperature
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion (GDP) strategy
Number of subjects: 166
Study: 35797431

Group type: EXPERIMENTAL
Intervention: Complex Active Lifestyle Intervention (CALSTI) consisting of 12 weeks progressive explosive resistance training (24 sessions) enhanced by a 24-week multi-factorial self-management programme (8 sessions)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Extended version of the self-management intervention (SEMAI; 12 sessions)
Number of subjects: 215
Study: 32732515

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (Sal/Val) treatment
Number of subjects: 137

Group type: COMPARATOR
Intervention: Enalapril treatment (Control)
Number of subjects: 137
Study: 32609733

Group type: EXPERIMENTAL
Intervention: Anogenital psoriasis
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Control group (non-anogenital psoriasis)
Number of subjects: 1905
Study: 35380645

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) glucocorticoid injection (triamcinolone acetonide, 40 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Intra-articular (IA) glucocorticoid injection (triamcinolone acetonide, 40 mg)
Number of subjects: 145
Study: 33122571

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with total intravenous anaesthesia (DEX‐TIVA)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 177
Study: 32446752

Group type: EXPERIMENTAL
Intervention: Internet + incentives
Number of subjects: 418

Group type: COMPARATOR
Intervention: Internet-only
Number of subjects: 418
Study: 34052706

Group type: EXPERIMENTAL
Intervention: 3D radiomic model
Number of subjects: 74

Group type: COMPARATOR
Intervention: 2D radiomic model
Number of subjects: 74
Study: 33004857

Group type: EXPERIMENTAL
Intervention: 3-day AMX+MET
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 7-day AMX+MET
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 34273550

Group type: EXPERIMENTAL
Intervention: Median filter (window 5×5)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Hybrid median filter
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Improved adaptive complex diffusion filter (IACDF)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No filter
Number of subjects: 151
Study: 32886243

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted, catheter directed thrombolysis (U-ACDT) using the EkoSonic Endovascular System
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard anticoagulation
Number of subjects: 3
Study: 32465270

Group type: EXPERIMENTAL
Intervention: <500 mg MMF/day
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: >2000 mg MMF/day
Number of subjects: 240

Group type: COMPARATOR
Intervention: All MMF dosing groups
Number of subjects: 240
Study: 35776252

Group type: EXPERIMENTAL
Intervention: HIV stigma reduction intervention
Number of subjects: 1540
Study: 33890819

Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 157

Group type: COMPARATOR
Intervention: atomoxetine
Number of subjects: 157
Study: 32462307

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for anxiety in children with ADHD
Number of subjects: 219
Study: 35684639

Group type: EXPERIMENTAL
Intervention: Workswell WIRIS Agro R infrared camera (WWARIC)
Number of subjects: 4
Study: 33744673

Group type: EXPERIMENTAL
Intervention: Increasing the maximum preweaned age within the first housing group
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Increasing mean environmental temperature within the first month of life
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Increasing mean volume of milk feeding
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Increasing the number of days between the cleaning out of calving pen
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Increasing the number of days between the cleaning out of group housing pens
Number of subjects: 1014
Study: 34352138

Group type: EXPERIMENTAL
Intervention: Zuranolone 30 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Zuranolone 45 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 33909356

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with wheat-grain moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoxetine hydrochloride capsule (20 mg once a day)
Number of subjects: 60
Study: 35708946

Group type: EXPERIMENTAL
Intervention: Close targets
Number of subjects: 266

Group type: COMPARATOR
Intervention: Distant targets
Number of subjects: 266
Study: 33245028

Group type: EXPERIMENTAL
Intervention: Fear appeal communication with high response efficacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fear appeal communication with low response efficacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fear and anxiety from threat information exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater positivity of cognitive responses
Number of subjects: 0
Study: 36476479

Group type: EXPERIMENTAL
Intervention: csDMARDs plus denosumab (60-mg subcutaneous injection once every 6 months for 12 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: csDMARD therapy alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: csDMARDs plus denosumab
Number of subjects: 43
Study: 33289818

Group type: EXPERIMENTAL
Intervention: early high‐dose recombinant human erythropoietin (rhEpo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 34812251

Group type: EXPERIMENTAL
Intervention: Buprenorphine added to lidocaine 2%
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (lidocaine 2% only)
Number of subjects: 21
Study: 32145017

Group type: EXPERIMENTAL
Intervention: HLPpred-Fuse prediction framework
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empirical cross-validation analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent test and case study
Number of subjects: 0
Study: 35458106

Group type: EXPERIMENTAL
Intervention: Low-FODMAPs Diet (LFD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tritordeum-Based Diet (TBD)
Number of subjects: 0
Study: 34280568

Group type: EXPERIMENTAL
Intervention: Antibacterial envelope
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6800

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6800
Study: 32961542

Group type: EXPERIMENTAL
Intervention: 20 mg memantine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 34882890

Group type: EXPERIMENTAL
Intervention: Deep Learning models based on sagittal, coronal, and axial MR images
Number of subjects: 304
Study: 33882525

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 33278026

Group type: EXPERIMENTAL
Intervention: Beliefs-only condition
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Approaches-only condition
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Combined beliefs and approaches condition
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 384
Study: 32276674

Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Number of subjects: 9
Study: 35869707

Group type: EXPERIMENTAL
Intervention: Gegen Qinlian Decoction combined with a Chinese herbal hot package
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Western medical treatment
Number of subjects: 100
Study: 32777456

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy educational tool with optional life expectancy information
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study: 32646453

Group type: EXPERIMENTAL
Intervention: Cemented TKA
Number of subjects: 110

Group type: COMPARATOR
Intervention: Uncemented TKA
Number of subjects: 110
Study: 35393385

Group type: EXPERIMENTAL
Intervention: pRBC+TXA
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: pRBC
Number of subjects: 763

Group type: COMPARATOR
Intervention: TXA
Number of subjects: 763

Group type: COMPARATOR
Intervention: Neither
Number of subjects: 763
Study: 34388377

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib
Number of subjects: 311

Group type: COMPARATOR
Intervention: Erlotinib only
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (in brain metastases subgroup)
Number of subjects: 311
Study: 32277868

Group type: EXPERIMENTAL
Intervention: Switch from protease inhibitors to rilpivirine (RPV)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Continue ritonavir-boosted protease inhibitors (control group)
Number of subjects: 84
Study: 36476171

Group type: EXPERIMENTAL
Intervention: Remimazolam 5 mg intravenously
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dexmedetomidine 0.6 µg/kg intravenously
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midazolam 0.025 mg/kg intravenously
Number of subjects: 150
Study: 32618713

Group type: EXPERIMENTAL
Intervention: Antenatal administration of uterotonics
Number of subjects: 2608

Group type: COMPARATOR
Intervention: Control group (live-born babies who died between day 8 and 28)
Number of subjects: 2608
Study: 34074611

Group type: EXPERIMENTAL
Intervention: Symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy-only
Number of subjects: 0
Study: 34761243

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Program for Educators (MBHPEduca)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Neuroscience for Education program (Neuro‐Educa; active control)
Number of subjects: 76
Study: 35840611

Group type: EXPERIMENTAL
Intervention: Probiotics, daily doses, duration of 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, daily doses, duration of 28 days
Number of subjects: 0
Study: 34840886

Group type: EXPERIMENTAL
Intervention: DBS on
Number of subjects: 18

Group type: COMPARATOR
Intervention: DBS off
Number of subjects: 18
Study: 36102961

Group type: EXPERIMENTAL
Intervention: Complex model
Number of subjects: 162

Group type: COMPARATOR
Intervention: MRI reported model
Number of subjects: 162

Group type: COMPARATOR
Intervention: Radscore model
Number of subjects: 162
Study: 32043304

Group type: EXPERIMENTAL
Intervention: Enteral hydration (via NGT bolus, NGT continuous, both, or oral)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Intravenous fluids (IV)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Both IV and enteral fluids
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: NGT bolus
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: NGT continuous
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Both NGT bolus and continuous
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Oral hydration
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Mix of NGT and oral hydration
Number of subjects: 505
Study: 33039508

Group type: EXPERIMENTAL
Intervention: Intervention group received educational materials (packed lunch planner, shopping list, information on sugar content, suggestions for healthier swaps) over a 4-week period.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group received no materials.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intervention group received educational materials.
Number of subjects: 17
Study: 33268143

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS) containing beta‐hydroxy‐beta‐methylbutyrate (HMB) with dietary counseling, two servings/day for 180 days.
Number of subjects: 811

Group type: COMPARATOR
Intervention: Placebo supplement with dietary counseling, two servings/day for 180 days.
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: ONS with dietary counseling
Number of subjects: 811
Study: 33399351

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) expression in UC/DEAC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) expression in FIGO 3 endometrioid carcinoma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) expression in serous carcinoma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) expression in carcinosarcoma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) expression in clear cell carcinoma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Association of AR expression with hormone receptors in UC/DEAC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HER2 expression in UC/DEAC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HER2 expression in other high-grade carcinomas
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Association of loss of AR with clinicopathologic parameters in UC/DEAC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Potential role of androgen inhibitors in management of UC/DEAC
Number of subjects: 16
Study: 33396496

Group type: EXPERIMENTAL
Intervention: Creative Music Therapy (CMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16
Study: 35209785

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR), n=64
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT), n=84
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Vocational Rehabilitation (VR)
Number of subjects: 148
Study: 34448866

Group type: EXPERIMENTAL
Intervention: Continuous cardiac rhythm monitoring for 30 days after randomization
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care (no mandated monitoring)
Number of subjects: 336